会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 10. 发明授权
    • Sustained release preparation for tissue regeneration therapy
    • 组织再生治疗的缓释制剂
    • US08617614B2
    • 2013-12-31
    • US12446157
    • 2007-10-18
    • Yoshiki SakaiTakahiro Uchida
    • Yoshiki SakaiTakahiro Uchida
    • A61K9/50A61K31/44A01N43/40
    • A61K31/4406A61K9/1647
    • The present invention provides a microsphere with a slow-release period from about two weeks to about four weeks following administration, to enable a higher content of a drug to be included, to suppress an initial burst of the drug, and to maintain an optimal, effective blood concentration during the slow-release period. In a microsphere containing a drug and polylactic acid/glycolic acid (PLGA) copolymer, the amount of PLGA copolymer per part by weight of the drug is from about 3 to about 10 parts by weight; the average particle size of the microsphere is from about 20 to about 50 μm; and (3) the PLGA copolymer has a weight-average molecular weight from about 10,000 to about 50,000 and a PLGA compositional ratio from about 75/25 to about 50/50. The microsphere promotes the production of various endogenous repair factors useful against various tissue disorders.
    • 本发明提供了一种在施用后约两周至约四周的缓释期的微球,以使得能够包含更高含量的药物以抑制药物的初始爆发,并保持最佳, 缓释期有效血药浓度。 在含有药物和聚乳酸/乙醇酸(PLGA)共聚物的微球中,每重量份药物的PLGA共聚物的量为约3至约10重量份; 微球的平均粒径为约20至约50μm; 和(3)PLGA共聚物的重均分子量为约10,000至约50,000,PLGA组成比为约75/25至约50/50。 微球促进了各种可用于各种组织疾病的内源性修复因子的产生。